Arrayit Corporation Reports Clinical Instrumentation Sale to the United States Food and Drug Administration
16 Luglio 2018 - 11:30AM
Sunnyvale, July 16, 2018 (GLOBE NEWSWIRE) -- July 16, 2018 -
Sunnyvale, CA – Arrayit Corporation (OTC: ARYC), a life sciences
and personalized medicine company, announces the sale of clinical
instrumentation to the United States Food and Drug Administration
(FDA). Arrayit uses the same clinical instrumentation in its
Clinical Laboratory Improvement Amendments (CLIA) laboratory
licensed by the Centers for Medicare and Medicaid Services (CMS)
and the State of California Department of Public Health
(CDPH). The instrumentation reads and reports test results
for the company’s allergy and dietary wellness tests and pipeline
tests for ovarian cancer and Parkinson’s Disease (PD).
Arrayit recently scored 100% on immunoglobulin E (IgE)
proficiency testing with the College of American Pathologists,
announced a nationwide sales network of 1,700 professional sales
representatives to sell and distribute the company’s finger stick
tests, and completed pilot testing with one the nation’s largest
chains of retail stores. Arrayit microarray tests
conveniently use a few drops of blood collected on a blood card to
assist doctors in identifying and treating allergy, asthma, dietary
intolerance and pipeline indications for ovarian cancer and
PD. The company recently met with top officials at the FDA to
discuss FDA approval of a major product line. The FDA ensures
the safety of food, drugs and medical devices by regulating
consumer products exceeding $1,000,000,000,000 ($1 trillion) in
annual revenues.
Arrayit CEO Rene Schena states, “The sale of clinical
instrumentation to the FDA advances our personalized medicine
initiatives by strengthening ties with the nation’s preeminent
regulatory agency. Our transformative healthcare products and
services benefit from transparency in the hands of top FDA
scientists.”
About Arrayit
Arrayit Corporation, headquartered in Sunnyvale, California, leads
and empowers the research, biotechnology, pharmaceutical, clinical
and healthcare sectors through the discovery, development and
manufacture of proprietary life science and personalized medicine
products and services to advance biomedical research and improve
wellness and human health. Please visit www.arrayit.com for more
information.
Safe Harbor Statement
We have identified forward-looking statements by using words such
as "expect", "believe", and "should". Although we believe our
expectations are reasonable, our operations involve a number of
risks and uncertainties that are beyond our control, and these
statements may turn out not to be true. Risk factors associated
with our business, including some of the facts set forth herein,
are detailed in the Company's public filings.
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
CONTACT
Public Relations
Arrayit Corporation
Tel: 408-744-1331
Email: arrayit@arrayit.com
Web: www.arrayit.com
Grafico Azioni Arrayit (CE) (USOTC:ARYC)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Arrayit (CE) (USOTC:ARYC)
Storico
Da Nov 2023 a Nov 2024
